

ViroGates Equity Story

ViroGates is an in-vitro diagnostic company focused on improving patient outcomes through developing and commercializing novel diagnostic tests. With a strong track record of innovation, the company has developed a unique technology platform that enables rapid and reliable measurement of its biomarker-product suPARnostic® in blood samples.

ViroGates is well-positioned to capture a significant share of the rapidly growing market for diagnostic tests, driven by the increasing demand for personalized and precision medicine. The company's flagship product, suPARnostic®, is a groundbreaking test that measures the level of suPAR, a protein biomarker associated with inflammation and disease severity, in patient blood samples. This test has demonstrated significant clinical utility in various diseases, including COVID-19, sepsis, cardiovascular disease etc.

ViroGates has a robust intellectual property portfolio, including multiple patents on its use cases. The company has also established strategic partnerships with leading healthcare organizations, including hospitals, academic institutions, and research centers, to further develop and validate its diagnostic tests.

With a highly experienced management team and a dedicated workforce, ViroGates is well-equipped to execute its growth strategy and capitalize on the significant market opportunity. The company is committed to expanding its product portfolio and commercializing its diagnostic tests globally, with a focus on high-growth markets in Europe and, subsequently, North America and Asia.

Investing in ViroGates offers the opportunity to participate in the growth of a cutting-edge in-vitro diagnostic company with a strong value proposition and significant market potential.

ViroGates Shares

ViroGates' shares (VIRO) have been listed on Nasdaq First North Growth Market Denmark since 2018.




Share Data		21/09/2023
Previous Close		20.50
Change (%)		2.50
Volume		148
Number of Shares		3,350,507
Market Cap		68.69

KEY FIGURES - DKK('000)	2022	2021
Income statement		
Net revenue	10,151	7,656
Operating profit/loss	-10,845	-18,790
Profit/loss for the year	-9,646	-17,663
Balance sheet		
Balance sheet total	17,539	20,229
Equity	16,088	16,426
Invested capital	6,898	4,815
Cash flows		
Cash flows from operating activities	-14,276	-21,437
Cash flows from investment related activities	-13	-4
Cash flows from financing activities	9,308	2,776
Total cash flows	-4,981	-18,666
Cash and cash equivalents	9,878	14,859
Ratios		
Rate of return	-185.2	-658.2
Number of employees, end of period	9	13
Market share price, end of period (DKK)	40.1	144.0


MAJOR SHAREHOLDERS

At the end of 2022, ViroGates had 1,685 registered shareholders. Three shareholders had notified shareholdings of 5% or more:

Shareholders (31/12/2022)	Number Of Shares	Percent Of Capital
N. P. Louis-Hansen ApS	859,075	25.64%
Ginnerup Capital ApS	342,665	10.23%
4AM ApS	342,632	10.23%



Sales by product (2022)



* Other includes analysis services, freight and handling